Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

EnteroMedics To Discuss Business Strategy And Financial Results For The Second Quarter Of 2017

EnteroMedics Inc.
Posted on: 02 Aug 17
EnteroMedics To Discuss Business Strategy And Financial Results For The Second Quarter Of 2017 Conference Call to be held on Tuesday, August 8, 2017 at 11:30 AM Eastern Time

PR Newswire

ST. PAUL, Minn., Aug. 2, 2017

ST. PAUL, Minn., Aug. 2, 2017 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ:ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders today announced that it will host a conference call to discuss strategic business updates and financial results for the second quarter of 2017 on Tuesday, August 8, 2017 at 11:30 AM Eastern Time.

Individuals interested in listening to the conference call may do so by dialing (877) 280-7473 for domestic callers or (707) 287-9370 for international callers, using Conference ID: 64730754. To access the live webcast or replay, please visit the events page of the investor relations section of the EnteroMedics website at: http://ir.enteromedics.com.

About EnteroMedics Inc.

EnteroMedics is a medical device company focused on the development and commercialization of technology to treat obesity and metabolic diseases. vBloc® Neurometabolic Therapy, delivered by an FDA-approved pacemaker-like device called the vBloc® System, is designed to help patients feel full and eat less by intermittently blocking hunger signals on the vagus nerve. EnteroMedics recently acquired the Gastric Vest System™ through its acquisition of BarioSurg, Inc. The Gastric Vest is an investigational, minimally invasive, laparoscopically implanted medical device being studied for weight loss in morbidly obese patients. The device wraps around the stomach, emulating the effect of conventional weight-loss surgery, and is intended to enable gastric volume reduction without permanently changing patient anatomy.

Sign up for EnteroMedics investor alerts and news at http://ir.enteromedics.com/alerts.cfm.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/enteromedics-to-discuss-business-strategy-and-financial-results-for-the-second-quarter-of-2017-300498091.html

SOURCE EnteroMedics Inc.

PR Newswire
www.prnewswire.com

Last updated on: 02/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.